Business
Sernova Highlights Achievements from the HemAcure Consortium in Developing a Novel Cell-Based Therapy for Hemophilia A
(via TheNewswire) A series of breakthroughs from the International HemAcur...
About this update from Sernova Biotherapeutics Inc
[{"type":"text","content":"Sernova Highlights Achievements from the HemAcure Consortium in Developing a Novel Cell-Based Therapy for Hemophilia A(via TheNewswire)\n \n \nA series of breakthroughs from the International HemAcure Consortium provides a novel cell-based treatment approach for people living with Hemophilia A which could reduce or eliminate the need for lifelong Factor VIII infusions\n\n\n \nLONDON, ONTARIO / TheNewswire / November 20, 2018 - Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH) a clinical-stage regenerative medicine company, highlights the achievements in developing a novel cell-based therapy in combination with Sernova's Cell Pouch(TM) for treatment of Hemophilia A. \n\n\n \nThe therapeutic significance of this work supports the HemAcure Consortium's concept that Factor VIII genetically corrected human cells from a blood sample of patients with Hemophilia A transplanted into the Cell Pouch can improve blood clotting. \n\n\n \n\"I am impressed with the achievements of this International Consortium within the limited time allowed. The technical teams worked closely together to complete this work in developing a first-in-world ex vivo gene therapy approach in an implanted vascularized medical device for the treatment of Hemophilia A.\" said Dr. David Lillicrap, Professor in the Department of Pathology and Molecular Medicine at Queen's University, member of the Medical Advisory Board of the World Federation of Hemophilia, and HemAcure Scientific Advisory Board member. \n\n\n \nA summary of the Consortium's achievements are as follows: \n\n\n \n\n\nIn blood donated from patients with Hemophilia A, endothelial outgrowth cells to be corrected for the Factor VIII gene were isolated and grown successfully in a specialized Good Manufacturing Process (cGMP) compliant medium developed by the Consortium.\n\n\n\nUsing a human Factor VIII gene insertion technique, the cells were corrected and confirmed to produce Factor VIII. \n\n\n\nA preliminary experiment showed these cells could release Factor VIII in the blood over time and improve blood clotting in an animal model of Hemophilia A, in preparation for transplant into the Cell Pouch.\n\n\n\nThe corrected cells were proven to be successfully replicated through a production scale-up process. Following amplification, these cells maintained their normal healthy behavior in producing Factor VI...